BAILI-BIOPHARMACEUTICAL CO., LTD., a biopharmaceutical company, and its wholly owned US subsidiary, SystImmune, Inc, announced Friday that it has signed a clinical trial collaboration and supply agreement with United Kingdom-based AstraZeneca (LSE :AZN) (STO: AZN) (NASDAQ : AZN).
The contract has been signed to assess the combination of Baili's cancer therapy, SI-B001, an EGFR x HER3 bispecific antibody, in combination with AstraZeneca's third-generation, irreversible epidermal growth factor receptor (EGFR) TKI, TAGRISSO (osimertinib), in a new Phase 2a study, sponsored and carried out by Baili, for patients with non-small cell lung cancer (NSCLC).
The product is a bispecific antibody aimed at the proprietary platform technology developed by Baili and SystImmune and can also induce endocytosis of EGFR and HER3, and down-regulate the levels of EGFR and HER3 tumour cells. During preclinical studies, the product is claimed to have showcased superior tumour killing activities. SI-B001 Phase 1 trials have indicated good safety and preliminary efficacy.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review